CoreSite Realty Corporation (NYSE:COR) delivers secure, reliable, high-performance data center, cloud access and interconnection solutions to a growing customer ecosystem across eight key North American markets. More than 1,375 of the world's leading enterprises, network operators, cloud providers, and supporting service providers choose CoreSite to connect, protect and optimize their performance-sensitive data, applications and computing workloads. Our scalable, flexible solutions and 460+ dedicated employees consistently deliver unmatched data center options  all of which leads to a best-in-class customer experience and lasting relationships.
IPO Year:
Exchange: NYSE
Website: CoreSite.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/26/2024 | $261.00 | Outperform | Leerink Partners |
1/3/2024 | $242.00 | Overweight | Barclays |
12/14/2023 | $213.00 | Equal Weight | Wells Fargo |
12/14/2021 | $162.00 → $170.00 | Buy → Neutral | Citigroup |
11/26/2021 | $136.00 → $170.00 | Sector Perform | RBC Capital |
11/16/2021 | Underweight → Equal-Weight | Barclays | |
11/16/2021 | $158.00 → $170.00 | Outperform → Neutral | Credit Suisse |
11/16/2021 | Outperform → Market Perform | Raymond James | |
10/29/2021 | $149.00 → $153.00 | Outperform | Raymond James |
10/29/2021 | $130.00 → $135.00 | Underweight | Wells Fargo |
UK MHRA marketing authorization follows recent European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) in the EU for the treatment of wet AMDInitial commercial launches of LYTENAVA™ (bevacizumab gamma) in the EU and UK anticipated in calendar Q1 2025Strategic partnership with Cencora (formerly AmerisourceBergen) to support the planned commercial launches of LYTENAVA in UK and EU ISELIN, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) for the treatment of retina diseases, today announced that the United
Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2024 on Wednesday, July 31, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on July 31, 2024. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer Robert P. Mauch, Executive Vice President & Chief Operating Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10
Cencora, Inc. (NYSE:COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $400 million in a private transaction. Cencora is also raising its fiscal year 2024 adjusted diluted earnings per share guidance to $13.35 to $13.55, up from the previous range of $13.30 to $13.50, to reflect a lower weighted average diluted share count, partially offset by higher net interest expense due to lower investment balances as a result of cash being used for share repurchases. This transaction is an example of the Company's opportunistic approach to share repurchases and the Company will now have completed
Walgreens Boots Alliance announces sale of Cencora, Inc. shares for proceeds of approximately $400 million from Cencora stock repurchase Proceeds to Walgreens Boots Alliance will be used primarily for debt paydown and general corporate purposes No change to ongoing collaboration and long-term strategic partnership Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced that it has sold shares of Cencora, Inc. (NYSE:COR) pursuant to a share repurchase by Cencora in the amount of approximately $400 million. With the transaction, Walgreens Boots Alliance's ownership of Cencora's common stock has decreased from approximately 13 percent to approximately 12 percent. Proceeds to
Revenue of $68.4 billion for the Second Quarter, a 7.8 Percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $2.09 and Adjusted Diluted EPS of $3.80 Adjusted Diluted EPS Guidance Range Raised to $13.30 to $13.50 for Fiscal 2024 Cencora, Inc. (NYSE:COR) today reported that in its fiscal year 2024 second quarter ended March 31, 2024, revenue increased 7.8 percent year-over-year to $68.4 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items
Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2024 on Wednesday, May 1, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 1, 2024. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer Robert P. Mauch, Executive Vice President & Chief Operating Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 min
CEO Steven H. Collis to Transition to Executive Chair; COO Robert P. Mauch to Become President and CEO Both Appointments Effective October 1, 2024 Company Reaffirms Fiscal Year 2024 Guidance Cencora, Inc. (NYSE:COR) today announced that Steven H. Collis will retire as President and Chief Executive Officer of the Company and transition to the role of Executive Chair of the Cencora Board of Directors, effective October 1, 2024. Robert P. Mauch, PharmD, PhD, current Chief Operating Officer of Cencora, will succeed Collis as President and CEO, and will also be appointed as a member of the Company's Board, effective the same date. "Steve's 30-year career at Cencora has been characterized
Cencora, Inc. (NYSE:COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of approximately $50 million in concurrence with Walgreens Boots Alliance's sale of Cencora shares pursuant to Rule 144 under the Securities Act of 1933, as amended. Cencora intends to repurchase shares from Walgreens Boots Alliance at the price per share equal to the price in the Rule 144 sale. The concurrent share repurchase will be made under Cencora's share repurchase program and the repurchased shares will be held in treasury. About Cencora Cencora is a leading global pharmaceutical solutions organization centered on improvi
Transaction Highlights Walgreens Boots Alliance announces sale of shares of Cencora, Inc. for proceeds of $992 million Approximately $942 million sold pursuant to Rule 144 along with a concurrent share repurchase by Cencora of approximately $50 million Proceeds to Walgreens Boots Alliance will be used primarily for debt paydown and general corporate purposes No change to ongoing collaboration and long-term strategic partnership Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced that it has sold shares of Cencora, Inc. (NYSE:COR) common stock pursuant to Rule 144 for proceeds of approximately $942 million and, subject to the completion of the Rule 144 sale, a concurre
Cencora, Inc. (NYSE:COR) today announced the closing of its public offering of $500 million aggregate principal amount of its 5.125% Senior Notes due 2034 (the "Notes"), in an underwritten registered public offering. The offering was made pursuant to an effective shelf registration statement Cencora filed with the Securities and Exchange Commission (the "SEC") on November 23, 2021. Cencora intends to use the net proceeds from the offering to redeem all of its 3.400% Senior Notes due May 15, 2024 (CUSIP 03073E AL9) (the "2024 Notes") with any remaining net proceeds to be used for general corporate purposes. The joint book-running managers for the offering were BofA Securities, Inc., Citi
11-K - Cencora, Inc. (0001140859) (Filer)
SD - Cencora, Inc. (0001140859) (Filer)
8-K - Cencora, Inc. (0001140859) (Filer)
8-K - Cencora, Inc. (0001140859) (Filer)
10-Q - Cencora, Inc. (0001140859) (Filer)
8-K - Cencora, Inc. (0001140859) (Filer)
8-K - Cencora, Inc. (0001140859) (Filer)
8-K - Cencora, Inc. (0001140859) (Filer)
8-K/A - Cencora, Inc. (0001140859) (Filer)
8-K - Cencora, Inc. (0001140859) (Filer)
SC 13G/A - CoreSite Realty Corp (0001490892) (Subject)
SC 13G - CoreSite Realty Corp (0001490892) (Subject)
SC 13G/A - CoreSite Realty Corp (0001490892) (Subject)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
4 - Cencora, Inc. (0001140859) (Issuer)
The communications industry veteran brings years of experience to NWS Network Wireless Solutions, LLC ("NWS"), a rapidly growing solutions and logistics provider to carriers and telecommunications contractors, announced today the appointment of Michael Millegan to its board. NWS is a portfolio company of Grain Management, LLC ("Grain"), a leading Washington, D.C.-based investment firm focused on the global communications sector. Mr. Millegan is a seasoned technology executive with several years of experience leading company strategy, including sales, marketing, supply chain operations, cell site build-out, and engineering. Currently, Mr. Millegan serves as an independent board director fo
Leerink Partners initiated coverage of Cencora with a rating of Outperform and set a new price target of $261.00
Barclays initiated coverage of Cencora with a rating of Overweight and set a new price target of $242.00
Wells Fargo initiated coverage of Cencora with a rating of Equal Weight and set a new price target of $213.00
Citigroup downgraded CoreSite Realty from Buy to Neutral and set a new price target of $170.00 from $162.00 previously
RBC Capital reiterated coverage of CoreSite Realty with a rating of Sector Perform and set a new price target of $170.00 from $136.00 previously
Barclays upgraded CoreSite Realty from Underweight to Equal-Weight
Credit Suisse downgraded CoreSite Realty from Outperform to Neutral and set a new price target of $170.00 from $158.00 previously
Raymond James downgraded CoreSite Realty from Outperform to Market Perform
Raymond James reiterated coverage of CoreSite Realty with a rating of Outperform and set a new price target of $153.00 from $149.00 previously
Wells Fargo reiterated coverage of CoreSite Realty with a rating of Underweight and set a new price target of $135.00 from $130.00 previously
4 - Cencora, Inc. (0001140859) (Issuer)
Cencora (NYSE:COR) has outperformed the market over the past 5 years by 8.06% on an annualized basis producing an average annual return of 21.25%. Currently, Cencora has a market capitalization of $44.28 billion. Buying $100 In COR: If an investor had bought $100 of COR stock 5 years ago, it would be worth $264.37 today based on a price of $224.84 for COR at the time of writing. Cencora's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by an
AbbVie Inc (NYSE:ABBV) has petitioned the U.S. Supreme Court to protect its corporate records, arguing that a lower court ruling threatens the confidentiality of attorney communications. The pharmaceutical company is seeking to overturn a decision by the 3rd U.S. Circuit Court of Appeals, stating that filing a sham patent-infringement lawsuit could override attorney-client privilege. The case stems from allegations in the Philadelphia federal court where drug wholesalers, including Cencora Inc (NYSE:COR) (formerly AmerisourceBergen) and McKesson Corporation (NYSE:MCK), claim they were overcharged for the testosterone replacement drug AndroGel. Also Read: AbbVie’s Parkinson’s Disease
Cencora (NYSE:COR) has outperformed the market over the past 5 years by 6.78% on an annualized basis producing an average annual return of 19.86%. Currently, Cencora has a market capitalization of $43.81 billion. Buying $100 In COR: If an investor had bought $100 of COR stock 5 years ago, it would be worth $247.56 today based on a price of $222.47 for COR at the time of writing. Cencora's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by an
Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Cencora (NYSE:COR) in the last three months. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 1 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $279.25, with a high estimate of $285.00 and a low estimate of $275.00. This upward trend is apparent,
Baird analyst David Rodgers maintains Cencora (NYSE:COR) with a Outperform and raises the price target from $280 to $285.
Cencora's (NYSE:COR) short percent of float has risen 7.85% since its last report. The company recently reported that it has 9.40 million shares sold short, which is 6.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.73 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is impo
Leerink Partners analyst Michael Cherny maintains Cencora (NYSE:COR) with a Outperform and maintains $275 price target.
Cencora (NYSE:COR) has outperformed the market over the past 5 years by 9.87% on an annualized basis producing an average annual return of 23.14%. Currently, Cencora has a market capitalization of $46.22 billion. Buying $1000 In COR: If an investor had bought $1000 of COR stock 5 years ago, it would be worth $2,800.32 today based on a price of $234.70 for COR at the time of writing. Cencora's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume PHR PUT TRADE NEUTRAL 06/21/24 $20.00 $570.0K 3.2K 3.1K LLY CALL SWEEP BEARISH 06/07/24 $850.00 $87.7
Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2024 on Wednesday, July 31, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on July 31, 2024. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer Robert P. Mauch, Executive Vice President & Chief Operating Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10
Revenue of $68.4 billion for the Second Quarter, a 7.8 Percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $2.09 and Adjusted Diluted EPS of $3.80 Adjusted Diluted EPS Guidance Range Raised to $13.30 to $13.50 for Fiscal 2024 Cencora, Inc. (NYSE:COR) today reported that in its fiscal year 2024 second quarter ended March 31, 2024, revenue increased 7.8 percent year-over-year to $68.4 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.09 for the second quarter of fiscal 2024 compared to $2.13 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items
Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2024 on Wednesday, May 1, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 1, 2024. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer Robert P. Mauch, Executive Vice President & Chief Operating Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 min
Revenue of $72.3 billion for the First Quarter, a 15.0% Percent Increase Year-Over-Year First Quarter GAAP Diluted EPS of $2.98 and Adjusted Diluted EPS of $3.28 Adjusted Diluted EPS Guidance Range Raised to $13.25 to $13.50 for Fiscal 2024 Cencora, Inc. (NYSE:COR) today reported that in its fiscal year 2024 first quarter ended December 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.98 for the first quarter of fiscal 2024 compared to $2.33 in the prior year first quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items
Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the First Quarter of Fiscal 2024 on Wednesday, January 31, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on January 31, 2024. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.
Revenue of $68.9 Billion for the Fourth Quarter, a 12.7 Percent Year-Over-Year Increase Fourth Quarter GAAP Diluted EPS of $1.72 and Adjusted Diluted EPS of $2.86 Revenue of $262.2 Billion for Fiscal Year 2023, a 9.9 Percent Year-Over-Year Increase Fiscal Year 2023 GAAP Diluted EPS of $8.53 and Adjusted Diluted EPS of $11.99 Cencora, Inc. (NYSE:COR), formerly AmerisourceBergen Corporation, today reported that in its fiscal year 2023 fourth quarter ended September 30, 2023, revenue increased 12.7 percent to $68.9 billion. Revenue increased 9.9 percent to $262.2 billion for the fiscal year. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per shar
Cencora, Inc. (NYSE:COR), formerly AmerisourceBergen Corporation, today announced that it plans to release its results for the Fourth Quarter of Fiscal 2023 on Thursday, November 2, 2023, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 2, 2023. Participating in the conference call will be: Steven H. Collis, Chairman, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of
CoreSite Realty Corporation ("CoreSite") (NYSE:COR), a subsidiary of American Tower Corporation ("American Tower") (NYSE:AMT), today announced year-end tax reporting information for its 2021 distributions. Stockholders are urged to consult with their personal tax advisors as to their specific tax treatment. On December 28, 2021, American Tower completed the acquisition of CoreSite through a merger of one of American Tower's wholly owned subsidiaries with and into CoreSite. In connection with the consummation of the merger, CoreSite's shares ceased trading on the New York Stock Exchange. CoreSite Realty Corporation Common Stock CUSIP 21870Q105 Former Ticker Symbol: COR Record Date
American Tower Corporation (NYSE:AMT) ("American Tower") announced today that it has closed its acquisition of CoreSite Realty Corporation (NYSE:COR) ("CoreSite") following the completion of its previously announced tender offer for all outstanding shares of common stock of CoreSite. American Tower completed the acquisition of CoreSite through a merger of one of its wholly owned subsidiaries with and into CoreSite. The closing was funded by borrowings under American Tower's revolving credit facilities and term loans. Tom Bartlett, American Tower's Chief Executive Officer stated, "We are thrilled to welcome CoreSite's exceptional team to American Tower and are ready to work together to crea
American Tower Corporation (NYSE:AMT) ("American Tower") announced today the expiration of its previously announced tender offer for all outstanding shares of common stock of CoreSite Realty Corporation (NYSE:COR) ("CoreSite"). American Tower intends to promptly complete the acquisition of CoreSite through a merger of one of its wholly owned subsidiaries with and into CoreSite. The previously announced tender offer expired one minute after 11:59 p.m. (Eastern time) on Monday, December 27, 2021, and was not extended. The depositary for the tender offer advised American Tower and CoreSite that immediately prior to the tender offer's expiration there were validly tendered and not validly with